LLY
VIVS
A $5 million breadcrumb from Lilly
VivoSim Labs woke up Wednesday with a fresh jolt of adrenaline: Eli Lilly sent over a $5 million milestone payment after dosing the first patient in a Phase 2 trial for VivoSim’s former inflammatory bowel disease program.
That may not sound like megacap money, but for a stock trading near penny-stock territory, it’s the kind of check that gets people leaning forward. Lilly can still unlock another $45 million in future milestones, so this isn’t just a one-and-done handshake. It’s a reminder that the old asset still has legs — and potentially more cash attached.
The real caffeine hit: FY2027 guidance
The company also tossed out FY2027 revenue guidance that points to more than 500% growth. That’s the kind of number that makes investors stop doomscrolling and start doing back-of-the-napkin math.
Why the optimism?
- VivoSim says demand is building for its next-gen 3D human cellular models
- Those models are used for preclinical safety screening, which is biotech-speak for "help me not build a drug that blows up later"
- The FDA’s push for more human-relevant testing models gives the business a nice tailwind
Why you should care
Shares jumped 18.36% to $0.98, which is still close to the 52-week low of $0.78, so this is definitely not a victory lap. It’s more like a company trying to climb out of a very deep hole while the market briefly hands it a ladder.
Big picture: milestone payments are nice, but the real story is whether VivoSim can turn these one-off wins into durable revenue growth instead of just another biotech pop-and-drop.